Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the target of unusually large options trading activity on Monday. Stock traders bought 13,040 call options on the stock. This represents an increase of 42% compared to the typical daily volume of 9,161 call options.

Insider Buying and Selling

In related news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,697,960.96. The trade was a 2.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 107,788 shares of company stock worth $724,691 in the last three months. Corporate insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC grew its stake in Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after buying an additional 1,795 shares during the period. Green Alpha Advisors LLC raised its position in Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the period. Interchange Capital Partners LLC lifted its stake in shares of Recursion Pharmaceuticals by 7.3% during the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after purchasing an additional 2,349 shares in the last quarter. Amalgamated Bank boosted its position in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 3.6 %

RXRX opened at $7.24 on Wednesday. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85. Recursion Pharmaceuticals has a 12 month low of $5.60 and a 12 month high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The business has a 50-day moving average of $6.76 and a two-hundred day moving average of $7.16.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same period last year, the company posted ($0.43) EPS. On average, research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

RXRX has been the topic of a number of recent research reports. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.